• Evercore ISI sets a price target of $144 for Abbott Laboratories (NYSE:ABT), indicating a potential increase of about 16.16%.
• The introduction of the Libre Assist feature within its Libre app, using AI to aid in diabetes management, could significantly enhance Abbott's market position.
• Abbott's current market capitalization stands at approximately $216.27 billion, with a recent slight stock price increase to $124.26.

Abbott Laboratories (NYSE:ABT) is a global healthcare company known for its innovative medical devices, diagnostics, and nutritional products. Competing with healthcare giants like Johnson & Johnson and Medtronic, Abbott has recently been spotlighted by Evercore ISI with a price target of $144, suggesting a potential increase of about 16.16% from its current trading price of $123.97.

Abbott's recent introduction of the Libre Assist feature within its Libre app is a significant development. Launched at CES 2026, this feature uses artificial intelligence to help people with diabetes make informed food choices. It predicts how different foods will affect glucose levels, offering real-time guidance before meals. This innovation could enhance Abbott's market position and drive stock growth.

The current price of ABT on the NYSE is $124.26, showing a slight increase of 0.05% or $0.07. The stock has traded between $122.50 and $124.30 today. Over the past year, ABT has seen a high of $141.23 and a low of $110.86. This price range indicates the stock's volatility and potential for growth.

Abbott's market capitalization is approximately $216.27 billion, reflecting its substantial presence in the healthcare sector. With a trading volume of 1,473,285 shares, the stock remains actively traded. The company's innovative products, like the Libre Assist, could further enhance its market value and attract more investors.